Camostat

Camostat

File:Camostat.svg
Gene therapy
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	B02AB04 (WHO)
Physiological data
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Identifiers
IUPAC name N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)phenylacetate
CAS Number	59721-29-8 Y (mesylate)
PubChem Template:Abbreviation	2536
ChemSpider	2440 Y
UNII	0FD207WKDU
ChEMBL	ChEMBL590799 Y
Chemical and physical data
Formula	C20H22N4O5
Molar mass	398.41 g/mol
3D model (JSmol)	Interactive image
SMILES CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N
InChI InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23) Y Key:XASIMHXSUQUHLV-UHFFFAOYSA-N Y
(verify)

Camostat (INN) is a serine protease inhibitor.

References

• Kunze H, Bohn E (May 1983). "Effects of the serine protease inhibitors FOY and FOY 305 on phospholipase A1 (EC 3.1.1.32) activity in rat - liver lysosomes". Pharmacol Res Commun. 15 (5): 451–9. doi:10.1016/S0031-6989(83)80065-4. PMID 6412250.
• Göke B, Stöckmann F, Müller R, Lankisch PG, Creutzfeldt W (1984). "Effect of a specific serine protease inhibitor on the rat pancreas: systemic administration of camostate and exocrine pancreatic secretion". Digestion. 30 (3): 171–8. doi:10.1159/000199102. PMID 6209186.CS1 maint: Multiple names: authors list (link)